E2F1 and breast carcinoma: The expression of MALAT1 was shown to be enhanced by METTL3 through recruitment of E2F transcription factor 1 (E2F1), resulting in transcription of anterior gradient 2 (AGR2), and subsequent adriamycin resistance in breast cancer (Li et al., 2022).